{"id":"W3161195108","doi":"10.1016/j.ejca.2021.04.004","title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Genentech; Eisai; U.S. Department of Defense; Exelixis; Congressionally Directed Medical Research Programs; Gateway for Cancer Research; Astellas Pharma; Ariad Pharmaceuticals; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Clinical Oncology; Intensive care medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006166858,0.0001930765,0.001091283,0.0003501381,0.0005288001,0.001317423,0.0003832585,0.0007135291,0.002623474],"category_scores_gemma":[0.01068947,0.00009388402,0.001067596,0.0007147047,0.0004049006,0.0008363418,0.0004811456,0.0007435736,0.0004476724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007020356,"about_ca_system_score_gemma":0.001124016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002578638,"about_ca_topic_score_gemma":0.0006018506,"domain_scores_codex":[0.9973841,0.001036091,0.0005628889,0.0002846603,0.0003913352,0.0003410142],"domain_scores_gemma":[0.9893802,0.003481623,0.004910988,0.0004392804,0.0005630438,0.001224701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05793297,0.001503605,0.8729368,0.00113024,0.001011137,0.0006427745,0.0005009485,0.001089265,0.002087991,0.000804323,0.00340775,0.05695223],"study_design_scores_gemma":[0.00879964,0.0193913,0.9472201,0.0005137067,0.001171266,0.001928807,0.0003418651,0.001522787,0.001663542,0.001922013,0.01547418,0.00005066792],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863391,0.005577013,0.0004161979,0.0007875648,0.00006611062,0.000765774,0.002440415,0.00001433185,0.003593517],"genre_scores_gemma":[0.9942636,0.0005896673,0.0002727405,0.0004946517,0.00006193583,0.0005499042,0.003400948,0.0000054631,0.0003609975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006166858,"threshold_uncertainty_score":0.03261387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1448300445939579,"score_gpt":0.4509421169423179,"score_spread":0.30611207234836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}